Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.48 |
| ▸ | ACACA | Q13085 | 2/20 | 0.48 |
| ▸ | EBP | Q15125 | 8/20 | 0.48 |
| ▸ | CDC25A | P30304 | 8/20 | 0.44 |
| ▸ | CDC25B | P30305 | 8/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050397 | 1.00 | ACLY (0.48) | ACLYACACAEBPCDC25ACDC25B | |
| SCHEMBL29934951 | 0.87 | CDC25A (0.59) | ACLYACACAEBPCDC25ACDC25B | |
| SCHEMBL14116745 | 0.85 | CDC25A (0.51) | ACLYACACAEBPCDC25ACDC25B | |
| SCHEMBL3285801 | 0.84 | ACLY (0.61) | ACLYACACAEBPPTPN11HSD11B1 | |
| SCHEMBL3285804 | 0.84 | ACLY (0.61) | ACLYACACAEBPPTPN11HSD11B1 | |
| SCHEMBL2450676 | 0.82 | CDC25A (0.46) | ACLYACACAEBPCDC25ACDC25B | |
| SCHEMBL2450675 | 0.82 | CDC25A (0.46) | ACLYACACAEBPCDC25ACDC25B | |
| Cycloartanol SCHEMBL12152356 | 0.81 | ACLY (0.67) | ACLYACACAEBPCDC25ACDC25B | |
| Cycloartanol SCHEMBL1881616 | 0.81 | ACLY (0.67) | ACLYACACAEBPCDC25ACDC25B | |
| Cycloartanol SCHEMBL13801860 | 0.81 | ACLY (0.67) | ACLYACACAEBPCDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 713 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338841-A1 | Dry Powdered Compositions and Methods and Uses Thereof | NEOZYME INTERNATIONAL, INC. (US) | 2025-11-06 | — | — | US | claimed |
| US-12356985-B2 | Dry powdered compositions and methods and uses thereof | NEOZYME INTERNATIONAL, INC. (US) | 2025-07-15 | — | — | US | claimed |
| CN-115363990-B | Lipid plant nutrient composition and preparation method and application thereof | 宜春大海龟生命科学股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| WO-2025043394-A1 | KIT FOR FORMING SUPRAMOLECULAR SELF-ASSEMBLY COMPLEX AND USE THEREOF | 北京睿创康泰医药研究院有限公司 | 2025-03-06 | — | — | WO | claimed |
| US-20240334927-A1 | Dry Powdered Compositions and Methods and Uses Thereof | NEOZYME INTERNATIONAL, INC. (US) | 2024-10-10 | — | — | US | claimed |
| CN-115724900-B | Dammarane type triterpenoid saponins compound, preparation method thereof and application thereof in preparation of hypoglycemic drugs | 广西师范大学 | 2024-06-07 | — | — | CN | claimed |
| US-11911489-B2 | Saponin-containing compositions for use in textile wipes and methods of use and preparation | SANJEEVITA BY AUDUBON, LLC (US) | 2024-02-27 | — | — | US | claimed |
| CN-116828996-A | Novel compositions for sour taste balance | 西姆莱斯有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116404255-A | Electrolyte additive for lithium ion battery and preparation method and application thereof | 湖北万润新能源科技股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-4142522-A1 | DRY POWDERED COMPOSITIONS AND METHODS AND USES THEREOF | Neozyme Inernational, Inc. (US) | 2023-03-08 | — | — | EP | claimed |
| US-20080193432-A1 | Compounds Having Estrogenic Activity | NATIONAL TAIWAN UNIVERSITY (TW) | 2008-08-14 | — | — | US | claimed |
| WO-2008028097-A2 | METHOD FOR SKIN CARE | NULIV HOLDING INC. (TW) | 2008-03-06 | — | — | WO | claimed |
| US-20080057010-A1 | METHOD FOR SKIN CARE | NULIV SCIENCE LTD. (TW) | 2008-03-06 | — | — | US | claimed |
| CN-101057854-A | Application of cycloartane type triterpenoids compound of cimicifuga rhizome for anti-osteoporosis and menopausal syndrome | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2007-10-24 | — | — | CN | claimed |
| CN-1225248-C | Antineoplastic effect of a group of cycloart-one triterpene compound | XIAO PEIGEN (CN) | 2005-11-02 | — | — | CN | claimed |
| CN-1524532-A | Antineoplastic effect of a group of cycloart-one triterpene compound | 肖培根 | 2004-09-01 | — | — | CN | claimed |
| CN-1162445-C | Jackfruit cycloalkane triterpenic saponin as one new compound and its application in the treatment of cardiovascular disease | 中国医学科学院药用植物研究所 | 2004-08-18 | — | — | CN | claimed |
| CN-1150204-C | Cyclobornane triterpenoid saponin compound and its application in immunosuppresion and treating tumor | 中国医学科学院药用植物研究所 | 2004-05-19 | — | — | CN | claimed |
| US-20040022914-A1 | Novel sweetener compositions and methods of use | ALLEN ANN DE WEES (US) | 2004-02-05 | — | — | US | claimed |
| WO-2003103415-A1 | NOVEL SWEETENER COMPOSITIONS AND METHODS OF USE | ALLEN ANN DE WEES (US) | 2003-12-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193432-A1 | Compounds Having Estrogenic Activity | ESRRA, ESRRG, ESR2 | ACLY 995/4885ACACA 1395/4885EBP 47/4885 |
| US-20080057010-A1 | METHOD FOR SKIN CARE | CUTA, GLA, BCAS2 | ACLY 330/4885ACACA 447/4885EBP 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.